Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650414 · ClinicalTrials.gov registry record · Phase 1
CD22 Redirected Autologous T Cells for ALL
A Phase 1 study of B-cell Lymphomas and B Cell Leukemias, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT02650414 is a Phase 1 study of B-cell Lymphomas and B Cell Leukemias that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 41 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02650414, a Phase 1 study of B-cell Lymphomas and B Cell Leukemias, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult subjects with relapsed or refractory B cell acute lymphoblastic leukemia.
Conditions Studied
Interventions
- BIOLOGICAL Cohort 1
- BIOLOGICAL Cohorts 2
- BIOLOGICAL Cohort 3
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-01-13 |
| Est. Completion | 2037-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02650414
The ClinicalTrials.gov registry entry for NCT02650414 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with B-cell Lymphomas appearing as the primary indexed condition, and to 3 interventions - of which Cohort 1 is the first listed.
NCT02650414 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02650414 about?
NCT02650414 is a clinical study titled "CD22 Redirected Autologous T Cells for ALL". This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult subjects with relapsed or refractory B cell acute...
What is the current status of trial NCT02650414?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-01-13. Estimated completion is 2037-12.
What conditions does trial NCT02650414 study?
This clinical trial studies the following conditions: B-cell Lymphomas, B Cell Leukemias.
What interventions are being tested in trial NCT02650414?
The interventions under investigation include: Cohort 1 (BIOLOGICAL), Cohorts 2 (BIOLOGICAL), Cohort 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02650414?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02650414 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Lymphomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.